Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for SELLAS Life Sciences Group, Inc. (SLS : NSDQ)
 
 • Company Description   
SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States.

Number of Employees: 15

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.19 Daily Weekly Monthly
20 Day Moving Average: 3,200,442 shares
Shares Outstanding: 99.78 (millions)
Market Capitalization: $218.51 (millions)
Beta: 2.31
52 Week High: $2.22
52 Week Low: $0.77
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 38.61% 32.60%
12 Week 110.58% 71.80%
Year To Date 110.58% 99.60%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
7 TIMES SQUARE SUITE 2503
-
NEW YORK,NY 10036
USA
ph: 646-200-5278
fax: 441-400-2875
ir@sellaslife.com http://www.sellaslifesciences.com
 
 • General Corporate Information   
Officers
Angelos M. Stergiou - Chief Executive Officer;President
John Varian - Chair of the Board of Directors
John T. Burns - Senior Vice President; Chief Financial Officer
David Scheinberg - Director
Robert Van Nostrand - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 81642T209
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 99.78
Most Recent Split Date: 11.00 (0.02:1)
Beta: 2.31
Market Capitalization: $218.51 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.28 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 7.46
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 66.67%
vs. Previous Quarter: 12.50%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -193.67
12/31/24 - -325.46
ROA
06/30/25 - -
03/31/25 - -113.02
12/31/24 - -144.49
Current Ratio
06/30/25 - -
03/31/25 - 4.64
12/31/24 - 1.72
Quick Ratio
06/30/25 - -
03/31/25 - 4.64
12/31/24 - 1.72
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 0.29
12/31/24 - 0.13
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©